In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Access to biologics for rheumatoid arthritis varies widely in Europe

This article was originally published in Scrip

Executive Summary

There are large inequalities in access to innovative biologic rheumatoid arthritis (RA) treatments across Europe, says a new study published in the European Journal of Health Economics. Variations in drug affordability, standardised prices and health technology assessments all take their toll on uptake to varying degrees.

You may also be interested in...



USCMA Revision Worsens Innovator Woes In Canada

Stripping the revised USMCA deal of provisions to strengthen IP rights for biologics will worsen market difficulties in Canada caused by changes to the drug pricing regime, says industry.

Calls to End Industry’s ‘Financial Entanglement’ With Healthcare Players

Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.

What’s Next After 20 Years Of NICE?

Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.

Topics

Related Companies

UsernamePublicRestriction

Register

SC005056

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel